Reports Q3 revenue $2.17M, consensus $820,800. “In the third quarter, we focused on developing BDC-4182, the first next-generation Boltbody ISAC in our pipeline. We are actively enrolling patients with gastric and gastroesophageal cancer in the Phase 1 dose-escalation study. We now look forward to presenting initial data in the third quarter of 2026,” said Willie Quinn, President and Chief Executive Officer. “With our cash runway now expected to extend into 2027, we are in a financial position to create long-term value for our shareholders and fulfill our mission of bringing new treatment options to patients with cancer.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLT:
- Bolt Biotherapeutics’ Pioneering Study on BDC-4182: A New Hope for Cancer Treatment
- Buy Rating for Bolt Biotherapeutics: Innovative Cancer Treatment Approach and Strategic Financial Management
- Bolt Biotherapeutics assumed with a Buy at H.C. Wainwright
- Bolt Biotherapeutics Announces Major Restructuring Plan
- Bolt Biotherapeutics to reduce workforce by 50%, gives update on BDC-4182 study